EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCBB:BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer’s disease, multiple sclerosis (MS), and traumatic brain injury, announced today that their exclusive worldwide licensor, Marv Enterprises, LLC has received a Notice of Allowance from the U.S. Patent and Trademark Office for 20 claims in their broad base patent application, “Utilization of Stents for the Treatment of Blood-Bourne Carcinomas,” covering the basic technology underpinning Premier’s on-going research into new treatments for many of today’s most debilitating diseases.
Help employers find you! Check out all the jobs and post your resume.
